Seeking Alpha

Analysts give the thumbs up to Bristol-Myers Squibb's (BMY -0.25%) and AstraZeneca's (AZN -1.2%)...

Analysts give the thumbs up to Bristol-Myers Squibb's (BMY -0.25%) and AstraZeneca's (AZN -1.2%) purchase of Amylin (AMLN). "The acquisition is a good strategic fit...with a sound financial basis and tangible economic benefits," says Deutsche Bank. UBS, Wells Fargo and Leerink Swann are also positive.
From other sites
Comments (2)
  • Stone Fox Capital
    , contributor
    Comments (7032) | Send Message
     
    The deal might be a good strategic fit, but the dilutive impact and the stock at 10 yr highs suggests selling the stock.
    2 Jul 2012, 11:50 AM Reply Like
  • Randy Sommovilla
    , contributor
    Comments (44) | Send Message
     
    The only thing I don't like about the deal is partnering with AZN.
    2 Jul 2012, 12:46 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs